Sarepta Therapeutics (NASDAQ:SRPT) Given New $125.00 Price Target at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT) had its target price dropped by equities research analysts at Needham & Company LLC from $183.00 to $125.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 242.28% from the company’s previous close.

Other analysts have also issued reports about the company. HC Wainwright reissued a “neutral” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, April 16th. Royal Bank of Canada cut shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $161.00 to $87.00 in a research note on Monday, March 31st. Scotiabank reduced their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Finally, Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.22.

Sarepta Therapeutics Stock Performance

SRPT opened at $36.52 on Wednesday. The firm has a fifty day moving average price of $68.17 and a 200 day moving average price of $101.49. Sarepta Therapeutics has a 1 year low of $35.46 and a 1 year high of $173.25. The stock has a market cap of $3.59 billion, a P/E ratio of 29.22 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter last year, the company posted $0.73 EPS. The company’s revenue was up 80.2% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Manchester Capital Management LLC increased its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC raised its stake in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.